Argenx to present pivotal advance trial data during ash plenary session highlighting vyvgart® (efgartigimod alfa-fcab) as potential new treatment modality for immune thrombocytopenia

First immune thrombocytopenia (itp) pl enary selection in 15 years underscores significant unmet need in this rare, serious autoimmune bleeding disease
ARGX Ratings Summary
ARGX Quant Ranking